Financial Analysis: NovaBay Pharmaceuticals (NBY) and AC Immune SA (ACIU)
NovaBay Pharmaceuticals (NYSE: NBY) and AC Immune SA (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
This is a summary of current recommendations and price targets for NovaBay Pharmaceuticals and AC Immune SA, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AC Immune SA||0||0||3||0||3.00|
NovaBay Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential upside of 62.79%. AC Immune SA has a consensus price target of $21.50, indicating a potential upside of 81.13%. Given AC Immune SA’s stronger consensus rating and higher possible upside, analysts plainly believe AC Immune SA is more favorable than NovaBay Pharmaceuticals.
Earnings & Valuation
This table compares NovaBay Pharmaceuticals and AC Immune SA’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|NovaBay Pharmaceuticals||$15.34 million||4.29||-$9.47 million||N/A||N/A|
|AC Immune SA||$5.83 million||116.15||-$34.66 million||N/A||N/A|
NovaBay Pharmaceuticals has higher revenue and earnings than AC Immune SA.
This table compares NovaBay Pharmaceuticals and AC Immune SA’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AC Immune SA||N/A||N/A||N/A|
Insider & Institutional Ownership
18.1% of AC Immune SA shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
AC Immune SA beats NovaBay Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company’s dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
About AC Immune SA
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.